ReviewFrontiers in immunology2026
Nanoparticles that modulate immune cells - an important strategy for the future treatment of tumors.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic Code Expansion Enables Oriented, Site-Specific Conjugation of DARPins to Lipid Nanoparticles for Selective mRNA Delivery to CD8International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer has become a major public health issue that seriously threatens human health. With the widespread development and application of drug-loaded nanosystems in tumor therapy, numerous studies have confirmed that various nanoparticles can exert anti-tumor activity by regulating one or more immune cells in the tumor microenvironment (TME), including depleting M2-type TAMs in the TME, limiting the recruitment and localization of TAMs, reprogramming M2-type TAMs into M1-type TAMs, enhancing NK cells homing or function, promoting DCs maturation, inhibiting TANs recruitment or altering their polarity, reducing circulating and tumor-infiltrating MDSCs, altering MDSCs phenotype or inhibiting MDSCs functions (including nanocapsules, metal-organic frameworks, micelles, polymers, dendritic macromolecules, liposomes, and other material nanoparticles), promoting CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.